We review last week’s biopharma news for meaningful clinical data, regulatory updates, research innovation, and M&A. Last week, BMY received landmark antipsychotic approval
What is covered in the Full Insight:
Bristol-Myers Squibb Approval
Biohaven Phase 3 Success
Amgen's Clinical Data
AstraZeneca and Daiichi Sankyo Setback
Pfizer's Oxbryta Withdrawal
SUMMARY
(Sign Up to Access)
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
Unlock research summaries
Follow top, independent analysts
Receive personalised alerts
Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.